Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Abstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229...
Guardado en:
Autores principales: | Yi-Sheng Chang, Wan-Ju Lee, Chen-Chee Lim, Shih-Hao Wang, Sheng-Min Hsu, Yi-Chian Chen, Chia-Yi Cheng, Yu-Ti Teng, Yi-Hsun Huang, Chun-Chieh Lai, Sung-Huei Tseng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf60fbae34e04c8eb45e500e819ecf7d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Tryfon Rotsos, et al.
Publicado: (2010) -
Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
por: Russo A, et al.
Publicado: (2018) -
Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016) -
Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)